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Risk Factors for Fecal Carriage of Extended-Spectrum
Beta-Lactamase Producing Escherichia coli and
Klebsiella spp. in the Community
Aim: Community-acquired infections caused by extended-spectrum beta-lactamase (ESBL)-producing bacteria
are an emerging problem. Digestive tract colonization is a prerequisite for infections by ESBL-producing
microorganisms. The aim of this study was to determine the prevalence of and risk factors for fecal carriage
of ESBL-producing Escherichia coli (E. coli) or Klebsiella spp. in the community.
Materials and Methods: A total of 928 stool samples admitted to the laboratory during a four-month period
were included in the study. Samples were diluted in saline and cultured in two EMB agar plates supplemented
with either 1 µg/ml cefotaxime or 1 µg/ml ceftazidime. All isolates that grew were identified to the species
level. E. coli and Klebsiella spp. strains were tested for ESBL production with ceftazidime and ceftazidimeclavulanate discs according to the Clinical and Laboratory Standards Institute (CLSI) Guideline.
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Results: Of the 928 stool samples included, 133 (14%) were isolated from inpatients and 795 (86%) from
outpatients. Sixty-three (47.3%) of 133 hospitalized and 121 (15.2%) of 795 outpatients harbored ESBLproducing E. coli and Klebsiella spp. (P = 0.000). Chronic hepatic failure (OR: 8.7, CI: 1.65-46.12; P = 0.011)
and recent antibiotic use (OR: 4.4, CI: 1.76-11.16; P = 0.002) were found to be associated with ESBL
positivity for the hospitalized patients. Recent antibiotic use (OR: 2.8, CI: 1.61-5.12; P = 0.000) was found
to be the only independent variable associated with ESBL positivity for the outpatients.
Conclusions: The high prevalence (15.2%) of fecal carriage of ESBL-producing bacteria in the community
warrants further study in this field including the consequences of this colonization in the hospital setting.
Key Words: ESBL positivity, fecal carriage, risk factors, E. coli, Klebsiella spp.

Toplumda D›ﬂk›da Geniﬂlemiﬂ-Spektrumlu Beta Laktamaz Salg›layan
Escherichia coli ve Klebsiella spp. Suﬂlar›n›n S›kl›¤›n›n Araﬂt›r›lmas›
Amaç: Geniﬂlemiﬂ spektrumlu beta-laktamaz (GSBL) enzimi üreten bakterilerle geliﬂen toplum kökenli
infeksiyonlar›n s›kl›¤› giderek artmaktad›r. GSBL salg›layan bakterilerle oluﬂan infeksiyonlar için ilk aﬂama
genellikle gastrointestinal sistem kolonizasyonudur. Bu çal›ﬂman›n amac›, toplumda d›ﬂk›da GSBL salg›layan
Escherichia coli ve Klebsiella spp. suﬂlar›n›n s›kl›¤›n›n araﬂt›r›lmas›d›r.
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Yöntem ve Gereç: Çal›ﬂmaya 4 ayl›k çal›ﬂma dönemi boyunca Mikrobiyoloji Laboratuvar›’na kabul edilen 928
d›ﬂk› örne¤i dahil edilmiﬂtir. Örnekler serum fizyolojik içinde suland›r›ld›ktan sonra 1 µg/mL sefotaksim ve 1
µg/mL seftazidim içeren EMB agar plaklar›na ekilmiﬂtir. Plaklarda üreyen tüm bakteriler tür düzeyine kadar
isimlendirilmiﬂtir. E. coli ve Klebsiella spp. suﬂlar› GSBL üretimi yönünden Clinical and Laboratory Standards
Institute (CLSI) önerileri do¤rultusunda seftazidim ve seftazidim-klavulonik asit diskleri ile test edilmiﬂtir.
Bulgular: Çal›ﬂmaya al›nan 928 örne¤in 133’ü (%14) yatan hastalardan, 795’i (%86) ayaktan hastalardan
elde edilmiﬂtir. Yatan 133 hastadan 63’ünde (%47.3) ve ayaktan baﬂvuran 795 hastan›n 121’inde (%15.2)
GSBL üreten E. coli veya Klebsiella spp. saptanm›ﬂt›r (P = 0.000). Yatan hastalarda GSBL pozitifli¤i için
ba¤›ms›z risk faktörleri; kronik karaci¤er yetmezli¤i (OR: 8.7; CI: 1.65-46.12; P = 0.011) ve yak›n zamanda
antibiyotik kullan›m› (OR: 4.4; CI: 1.76-11.16; P = 0.002) olarak belirlenmiﬂtir. Ayaktan hastalarda ise GSBL
pozitifli¤i yönünden belirlenen tek ba¤›ms›z risk faktörü yak›n zamanda antibiotik kullan›m›d›r (OR: 2.8; CI:
1.61-5.12; P = 0.000).
Sonuç: Toplumda GSBL pozitifli¤i yönünden saptanan %15.2’lik yüksek oran›n hastaneye yat›ﬂ durumunda
do¤urabilece¤i sonuçlar› irdeleyen klinik çal›ﬂmalara gereksinim vard›r.
Anahtar Sözcükler: GSBL pozitifli¤i, d›ﬂk› taﬂ›y›c›l›¤›, risk faktörleri, E. coli, Klebsiella spp.
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Introduction
Beta-lactamase production is the most common
mechanism of bacterial resistance to beta-lactam
antibiotics (1). Extended-spectrum beta-lactamases
(ESBL) were first described in 1983 in Europe and
were first reported from the United States in 1989
(2,3). Since then, infections due to ESBL-producing
bacteria have increased sharply (4). Besides nosocomial
infections, community-acquired infections caused by
ESBL-producing bacteria are an emerging problem
worldwide (5). Possible community acquisition of
ESBL-producing bacteria was first reported in the
urine of an elderly patient in 1998. The patient did not
have a recent history of hospitalization but had
received multiple courses of antibiotics (6). Risk
factors for the development of infections caused by
ESBL-producing bacteria in nonhospitalized patients
were reported to be previous hospitalization in the
past three months, antibiotic treatment in the past
three months, age over 60 years, diabetes mellitus,
male gender and Klebsiella pneumoniae infection (7).
Digestive tract colonization is also a prerequisite for
infections by ESBL-producing microorganisms (8). This
issue was studied in the setting of an outbreak or in
the patients admitted to an intensive care unit
(9,10,11). Recently, Valverde and co-workers (12)
reported an increase in prevalence of fecal carriage of
ESBL-producing bacteria in the community. Millar and
co-workers (13) screened healthy children for the
carriage of antibiotic-resistant bacteria in mouth
washings or stool samples. It was concluded that
antibiotic-resistant bacteria are widely disseminated
and may be acquired by children before exposure to
specific selection pressure.
The aim of this study was to determine the prevalence
of and risk factors for fecal carriage of ESBL-producing
Escherichia coli (E. coli) or Klebsiella spp. in the
community. To our knowledge, this is the first study
reporting the prevalence of fecal carriage of ESBLproducing bacteria in Turkey and also the first study
reporting the risk factors for fecal carriage of ESBLproducing bacteria in the community.
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Materials and Methods
Patients and Data Collection
The stool samples admitted to the Microbiology
Laboratory of Baﬂkent University Hospital between the
period of 1 June - 30 September 2005 were included in
the study. One sample from each patient was included. A
structured form was filled from the medical records of
the patients, and collected data about demographic
characteristics (age, sex), co-morbidities (chronic renal
failure, chronic hepatic failure, diabetes mellitus,
malignancy, transplantation), hospitalization within the
last three months, and antibiotic usage in the last three
months. One thousand and thirty-five stool samples from
individual patients were admitted to the laboratory
during the study period. Forms for 107 of these samples
could not be completed because of insufficient data and
were excluded.
This project was approved by the Baﬂkent University
Research Committee and was funded by Baﬂkent
University Research Foundation. Informed consent was
not required because there was no patient intervention.
Laboratory Methods
Samples were processed immediately after collection.
A total of 0.5 g of each fecal sample was suspended in 5
ml of saline and aliquots of 200 mL were seeded into two
EMB agar plates (Oxoid Ltd., Basingstoke, England) - one
supplemented with 1 mg of cefotaxime per ml, the other
supplemented with 1 mg of ceftazidime per ml and
incubated at 37°C for 48 hours (12). These selective
mediums with ceftazidime and cefotaxime were chosen
because they inhibit the growth of susceptible gramnegative pathogens, yet still permit the isolation of ESBLproducing bacteria. All isolates that grew were identified
to the species level. For this purpose, standard
biochemical reactions were performed at the first step
and BBL Crystal Enteric/NF 4.0 identification kits (Becton
®
Dickinson ) were used when needed. E. coli and Klebsiella
spp. strains were tested for ESBL production with
ceftazidime and ceftazidime-clavulanate discs according to
the Clinical and Laboratory Standards Institute (CLSI)
Guideline (14). In this test, a ≥5 mm increase in zone
diameter for ceftazidime/clavulanate disc versus
ceftazidime disc alone demonstrates that the strain has
the ESBL enzyme (14). When performing the ESBL
confirmatory tests, E. coli ATCC 25922 (negative
control) and Klebsiella pneumoniae ATCC 700603
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(positive control) were tested as quality control strains
(14). ESBL-producing isolates were tested against
amikacin, amoxicillin-clavulanate, ampicillin-sulbactam,
cefepime, ciprofloxacin, fosfomycin, gentamicin,
imipenem, meropenem, nalidixic acid, nitrofurantoin,
ofloxacin,
piperacillin-tazobactam,
sulfisoxazole,
ticarcillin-clavulanate
and
trimethoprimsulfamethoxazole. Antimicrobial susceptibility testing was
performed by disc diffusion method according to the CLSI
criteria (14). Quality was assured by testing E. coli ATCC
25922 and Pseudomonas aeruginosa ATCC 27853 in
every batch. All zone determinations for these strains
were within the ranges given by CLSI for the antibiotics
tested in this study (14).
Statistical Methods
Data were analyzed using Stata Statistical Software,
version 8.0 (STATA Corporation, Texas, USA).
Proportion comparisons for categorical variables were
done using chi-square tests, although Fisher’s exact test
was used when data were sparse. Significance was set at
P < 0.05 using two-sided comparisons. A multivariate
model was performed for ESBL positivity. In multivariate
analysis, backward and forward selections revealed the
same variables with the same odds ratios (OR) and
confidence intervals (CI).

February 2007

Results
Nine hundred and twenty-eight stool samples were
included in the study. One sample was taken from each
patient. Four hundred and forty-four (48%) of 928
patients were male. The mean age was 33.3 years with a
range of 3 months-95 years. One hundred and thirtythree (14%) of 928 patients were hospitalized and 795
(86%) were ambulatory at the time of study. A total of
184 ESBL-producing bacteria were isolated, of which
170 (92%) were E. coli and 14 (8%) were Klebsiella spp.
(9 Klebsiella oxytoca, 5 Klebsiella pneumoniae). Of the
170 E. coli strains, 55 (32%) were isolated from
inpatients and 115 (68%) from outpatients.
Sixty-three (47.3%) of 133 inpatients and 121
(15.2%) of 795 outpatients harbored ESBL-producing
bacteria (P = 0.000). In univariate analysis including both
inpatients and outpatients, chronic renal failure (P =
0.001), diabetes mellitus (P = 0.027), malignancy (P =
0.001), chronic hepatic failure (P < 0.001),
hospitalization at the time of study (P < 0.001), recent
hospitalization (P < 0.001), and recent antibiotic use (P
< 0.001) were found to be significantly associated with
ESBL positivity (Table 1). In multivariate analysis,
hospitalization at the time of study (OR: 3.3, CI: 2.175.11; P = 0.000), recent antibiotic use (OR: 3.3, CI:
2.17-5.11; P = 0.000), and chronic hepatic failure (OR:

Table 1. Univariate analysis of ESBL positivity among E. coli and Klebsiella spp. (n = 928).

Male
Co-morbidities
Chronic renal failure
Diabetes mellitus
Malignancy
Chronic hepatic failure
Transplantation2
Hospitalization3
Recent hospitalization4
5
Recent antibiotic use
Recent quinolone use
Recent beta-lactam use
1
2
3
4
5

Total
n = 928

ESBL positivity
n = 184 (%)

P
value

444

96 (22)

NS1

62
58
44
38
45
133
131
135
18
91

22
18
17
16
13
63
49
62
10
44

(35)
(31)
(39)
(42)
(29)
(47)
(37)
(46)
(56)
(47)

0.001
0.027
0.001
< 0.001
NS
<0.001
<0.001
<0.001
<0.001
<0.001

Non-significant
Renal or liver transplantation
Hospitalization at the time of study
Hospitalization in the previous 3 months
Antibiotic use in the previous 3 months
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3.3, CI: 2.17-5.11; P = 0.000) were found to be
associated with ESBL positivity (Table 2). Patients were
then categorized into two groups according to
hospitalization at the time of study and multivariate
analysis was performed for each group. Chronic hepatic
failure (OR: 8.7, CI: 1.65-46.12; P = 0.011) and recent
antibiotic use (OR: 4.4, CI: 1.76-11.16; P = 0.002) were
found to be associated with ESBL positivity for the
hospitalized patients (Table 3). Although recent antibiotic
use (P < 0.001) and beta-lactam use (P = 0.001) were
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found to be associated with ESBL positivity in the
univariate analysis, recent antibiotic use (OR: 2.8, CI:
1.61-5.12; P = 0.000) was found to be the only
independent variable associated with ESBL positivity for
outpatients in the multivariate analysis (Tables 4, 5). Risk
factors for ESBL positivity are summarized in the Figure.
There was no statistically significant difference
between the susceptibility rates of ESBL-producing E. coli
strains isolated from hospitalized patients and ambulatory
patients (Table 6).

Table 2. Multivariate analysis of ESBL positivity among E. coli and Klebsiella spp. (n = 928).
Odds ratio

Confidence interval

P value

1.0

0.99-1.00

NS1

Male

0.8

0.61-1.23

NS

Chronic renal failure

1.1

0.59-2.17

NS

Age

Diabetes mellitus

1.4

0.73-2.81

NS

Chronic hepatic failure

2.1

1.05-4.54

0.035

Hospitalization2

3.3

2.17-5.11

0.000

Recent hospitalization3

0.8

0.51-1.52

NS

3.0

1.99-4.67

0.000

4

Recent antibiotic use
1
2
3
4

Non-significant
Hospitalization at the time of study
Hospitalization in the previous 3 months
Antibiotic use in the previous 3 months

Table 3. Multivariate analysis of ESBL positivity among E. coli and Klebsiella spp. isolated from
hospitalized patients (n = 133).

Age

Confidence interval

P value

1.0

0.99-1.02

NS1

Gender

0.7

0.34-1.72

NS

Chronic renal failure

1.0

0.38-2.81

NS

Diabetes mellitus

2.4

0.67-8.55

NS

Chronic hepatic failure

8.7

1.65-46.12

0.011

Recent hospitalization2

1.3

0.55-3.36

NS

Recent antibiotic use3

4.4

1.76-11.16

0.002

1
2
3
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Non-significant
Hospitalization in the previous 3 months
Antibiotic use in the previous 3 months
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Table 4. Univariate analysis of ESBL positivity among E. coli and Klebsiella spp. isolated from
outpatients (n = 795).
Total
n = 795

ESBL positivity
n = 121 (%)

P
value

372

59 (16)

NS1

Chronic renal failure

33

7 (21)

NS

Diabetes mellitus

42

8 (19)

NS

Malignancy

24

5 (21)

NS

Chronic hepatic failure

25

5 (20)

NS

Transplantation2

26

4 (15)

NS

67

10 (15)

NS
<0.001

Male
Co-morbidities

Recent hospitalization3
4

Recent antibiotic use

75

22 (29)

Recent quinolone use

8

2 (25)

NS

Recent beta-lactam use

51

16 (31)

<0.001

1

Non-significant

2

Renal or liver transplantation

3

Hospitalization in the previous 3 months

4

Antibiotic use in the previous 3 months

Table 5. Multivariate analysis of ESBL positivity among E. coli and Klebsiella spp. isolated from
outpatients (n = 795).

Age

Odds ratio

Confidence interval

P value

1.0

0.99-1.01

NS1

Gender

0.8

0.59-1.31

NS

Chronic renal failure

1.4

0.54-3.61

NS

Diabetes mellitus

1.1

0.50-2.82

NS

Chronic hepatic failure

1.2

0.45-3.56

NS

Recent hospitalization2

0.5

0.25-1.27

NS

Recent antibiotic use3

2.8

1.61-5.12

0.000

1
2
3

Non-significant
Hospitalization in the previous 3 months
Antibiotic use in the previous 3 months

Discussion
Colonization with multi-resistant isolates, including
ESBL-producing isolates, is a prerequisite for infection.
The importance of the detection of carriers harboring
antimicrobial-resistant bacteria has been emphasized
not only in patient populations but also in healthy
people (15). Resistant bacteria may be transmitted
from human-to-human or through the environment

resulting in an increase in the proportion of carriers in
the community (16). The admission of carriers
harboring resistant bacteria to hospitals increases the
risk of infection in other hospitalized patients (4,17).
Antibiotic selective pressure in hospitals may amplify
the number of carriers harboring resistant bacteria and
enhance the opportunity for these bacteria to cause
infections (17).
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All patients admitted
to the microbiology
laboratory (n=928)

Hospitalization (OR: 3.3, CI: 2.17-5.11; p=0.000)
Recent antibiotic use (OR: 3.3, CI: 2.17-5.11; p=0.000)
Chronic hepatic failure (OR: 3.3, CI: 2.17-5.11; p=0.000)

Hospitalized

Outpatients

patients

(n=795)

(n=133)

Recent antibiotic use

Recent antibiotic use

(OR: 4.4, CI: 1.76-11.16; p=0.002)

(OR: 2.8, CI: 1.61-5.12; p=0.000)

Chronic hepatic failure
(OR: 8.7, CI: 1.65-46.12; p=0.011)
Figure. Summary of risk factors for ESBL positivity.

Table 6. The susceptibility rates of ESBL-producing E. coli strains against antimicrobial agents
(n = 170).

Amikacin
Amoxicillin-clavulanate
Ampicillin-sulbactam
Cefepime
Ciprofloxacin
Fosfomycin
Gentamicin
Imipenem
Meropenem
Nalidixic acid
Nitrofurantoin
Ofloxacin
Piperacillin-tazobactam
Sulfisoxazole
Ticarcillin-clavulanate
Trimethoprim-sulfamethoxazole
1 Non-significant
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Total
n = 55 (%)

ESBL positivity
n = 115 (%)

P
value

43 (78)
7 (13)
7 (13)
12 (22)
15 (27)
54 (98)
23 (42)
55 (100)
55 (100)
15 (27)
53 (96)
15 (27)
37 (67)
15 (27)
20 (36)
18 (33)

99 (86)
15 (13)
15 (13)
31 (27)
45 (39)
113 (98)
49 (43)
115 (100)
115 (100)
37 (32)
104 (90)
45 (39)
77 (67)
20 (17)
48 (42)
28 (24)

NS1
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
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Several studies have focused on beta-lactam resistance
in Enterobacteriaceae isolated from stools in healthy
people, but they did not specifically investigate ESBLs
(18,19). Recently, Mirelis (20) reported that 2.1% of
outpatients were fecal carriers of ESBL–producing
bacteria in 2001 and this percentage increased to 3.8%
one year later. Valverde (12) also reported that rates of
fecal carriage of ESBL-producing isolates increased
significantly (P < 0.001) in both hospitalized patients and
outpatients, from 0.3% and 0.7%, respectively, in 1991
to 11.8% and 5.5%, respectively, in 2003. The rate of
ESBL-producing isolates among healthy volunteers was
reported to be 3.7%. In the present study, 63 (47.3%)
of 133 inpatients and 121 (15.2%) of 795 outpatients
harbored ESBL-producing bacteria (P = 0.000).
Inpatients were not further categorized into intensive
care unit patients or ward patients. Because this study
was not planned to determine the prevalence of ESBL
positivity in hospitalized patients, stool samples were not
obtained from all patients in the hospital. So this high rate
(47.3%) among inpatients is probably far from the actual
rate. The prevalence of ESBL harboring E. coli or
Klebsiella spp. is strikingly high (15.2%) among
outpatients. The definition of “outpatients” in the present
study obviously does not correspond to “healthy
volunteers”. Stool samples of these patients were
admitted to the microbiology laboratory usually because
the patient had diarrhea, but because they were not
hospitalized at the time of study, they were considered as
presenting the community profile.
Until recently, most infections caused by ESBLproducing E. coli or Klebsiella spp. have been described as
nosocomially acquired or nursing home-related (1,21).
However, some recent data suggest that infections due to
ESBL-producing microorganisms might be an emerging
problem in the outpatient setting (5,6,7,22). Previous
antimicrobial treatment, older age, diabetes mellitus, and
previous hospitalization were identified as risk factors for
community-acquired infections caused by ESBL-producing
bacteria in two articles (7,22). To our knowledge, risk
factors for fecal carriage of ESBL-producing E. coli and
Klebsiella spp. in the community have not been studied. In
the present study, recent antibiotic use was determined
as the only independent variable in outpatients.
Surprisingly, hospitalization in the previous three months
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was not found to be associated with ESBL positivity.
Although older age and diabetes mellitus were found to
be risk factors for community-acquired infections caused
by ESBL-producing bacteria, no relation between age,
underlying disease and fecal carriage of bacteria
harboring ESBL could be demonstrated (7,22). Among
the recent antibiotics used, only beta- lactams and not
quinolones were found to be significantly associated with
ESBL positivity among outpatients. This finding is also
distinct from the other two studies which demonstrated
that previous quinolone use was one of the risk factors
for community-acquired infections caused by ESBLproducing bacteria (7,22).
Uropathogens are assumed to originate primarily
from the bowel flora, i.e. resistance in urinary isolates is
closely associated with the resistance in the fecal bacteria
(23). This is one of the reasons for giving careful
attention to this issue. ESBL-producing isolates are
known to be frequently resistant to antimicrobial classes
including aminoglycosides, quinolones and trimethoprimsulfamethoxazole (24). Multi-drug resistance causes
difficulties in the management of urinary tract infections.
Table 6 shows the susceptibility rates of the antibiotics
including fosfomycin, nitrofurantoin and sulfisoxazole
against 170 E. coli strains isolated from inpatients and
outpatients. These three antibiotics were tested because
E. coli is the most common cause of urinary tract
infections. Recently, ESBL production was found to be
significantly associated with ciprofloxacin resistance in
urinary E. coli isolates (25). The susceptibility rates were
also found to be low in the present study for the ESBLproducing E. coli strains. There was no statistically
significant difference between the strains isolated from
inpatients and outpatients (Table 6).
In conclusion, community-acquired infections caused
by ESBL-producing bacteria are an emerging problem.
Digestive tract colonization of resistant bacteria is a
prerequisite for infection. When urinary system infections
are taken into consideration, a high prevalence (15.2%)
of fecal carriage of ESBL-producing bacteria in the
community will probably cause difficulties in the
treatment of outpatients. These findings warrant further
study in this field including the consequences of
colonization with ESBL-producing bacteria both in the
community and in the hospital setting.
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